Nanosphere Announces Significate Study Results


Nanosphere, Inc. recently announced publication of a study that demonstrates the clinical and economic impact of implementing rapid sepsis diagnostic testing with the company’s FDA-cleared Verigene Gram-Positive Blood Culture Test (BC-GP) in a pediatric patient population. The pre-post outcomes study was conducted at Children’s Hospital Los Angeles in Los Angeles, CA, and published in Archives of Pathology & Lab Medicine.

“Our study is the first to assess the clinical and economic impact of BC-GP in a pediatric population,” said Jennifer Dien Bard, PhD, D (ABMM), FCCM, Director of the Clinical Microbiology Laboratory at Children’s Hospital Los Angeles. “We saw a decrease in morbidity, mortality, length of stay, and hospital costs for pediatric patients with gram-positive bloodstream infections after implementing BC-GP.”

The statistically significant results of the study included 5.6-day median length-of-stay reduction for patients with S. aureus bloodstream infections (8.9 versus 14.7 days), 1.9-day overall median hospital length-of-stay reduction per patient (7.2 versus 9.1 days), 39.6-hour reduction in antimicrobial exposure for patients with contaminated blood cultures (28.1 versus 67.7 hours), and 12.5-hour reduction in overall time to antimicrobial optimization (34.1 versus 46.6 hours).

“The findings from this study illustrate the profound impact the Verigene System can have on the care and outcomes for one of the highest risk patient populations,” said Michael McGarrity, Nanosphere’s President and Chief Executive Officer.

Contributors to the manuscript, Impact of a Rapid Blood Culture Assay for Gram-Positive Identification and Detection of Resistance Markers in a Pediatric Hospital, include Susanna Felsenstein, Jeffrey Bender, Matthew Gentry, Carol Takemoto, and Jennifer Dien Bard.

Nanosphere is enhancing medicine through targeted molecular diagnostics that result in earlier disease detection, optimal patient treatment, and improved healthcare economics. The company’s versatile technology platform, the Verigene System, enables clinicians to rapidly detect the most complex, costly, and deadly infectious diseases through a low-cost and simple-to-use multiplexed diagnostic test. The combination of this innovative technology and Nanosphere’s customer-driven solutions keeps commitment to the patient at the forefront of its business. Nanosphere is based in Northbrook, IL. For more information, visit www.nanosphere.us.